Percutaneous Electrical Nerve Stimulation or Transcutaneous Electrical Nerve Stimulation for Pain in Patients With Pancreatic Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pain
- Sponsor
- Fuda Cancer Hospital, Guangzhou
- Enrollment
- 36
- Locations
- 1
- Primary Endpoint
- visal analogue scale (VAS) score
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This study evaluates the effect of percutaneous electrical nerve stimulation (PENS) and transcutaneous nerve stimulation (TENS) for pain relieving in patients with pancreatic cancer. Patients will randomly allocated into PENS group, Tens group and control group.
Detailed Description
PENS and TENS have been reported with analgesic effect in patients with pain, including cancer pain, lower back pain, neck pain, stomachache and so on. Effect and mechanism of PENS on pain relieving has been widely researched. With additional electrical stimulation in certain frequency and intensity to conventional acupuncture, pain controlling effect has been largely enhanced. However, invasive operation limits its application and acceptability, especially on pancreatic cancer. TENS is an advanced technique generated from PENS, which is much more welcome for its noninvasive character. Further more, its analgesic effect on cancer pain has been proved by several multi-central, randomized, clinical trials.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Pancreatic cancer with pain;
- •Haven't underwent neurolytic celiac plexus block in the past 1 month;
- •With anticipatory survival of more than 3 months.
Exclusion Criteria
- •Metastatic pancreatic cancer;
- •Can not tolerate 30 min of lieing in prostrate or side position;
- •Who has been recruited in other clinical trial for pain releiving;
- •Who underwent radiotherapy or local radiactive seeds implantation for pain releiving in the past month;
- •Imaging diagnosed with encephalic tumor or metastasis;
- •Who with cardiac pacemaker or metal stand;
Outcomes
Primary Outcomes
visal analogue scale (VAS) score
Time Frame: D0-D6
VAS score before,during and 3 days after treatment
Secondary Outcomes
- quantity of analgesic medication(D0-D6)
- times of breakthrough pain (BTP)(D0-D6)